OM336 for Sjogren's disease or inflammatory muscle disease
Tests the safety of OM336 injections in adults with Sjogren's disease or myopathy.
Key facts
- Who runs it
- Lakefront Biotherapeutics West LLC
- Where
- Hamilton, New ZealandSee the siteAlso in 1 other country, 1 site
- Trial code
- NCT07229144
- EU 2025-524100-29-00
- ISRCTN16355728
- Registry title
- OM336 in Seropositive Autoimmune Diseases
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 39 people, planned
- Started
- 1 Oct 2025
- Expected to end
- Mar 2028
- Type of study
- Interventional
- Treatments tested
- OM336
- Record updated
- 15 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active Sjogren's disease or idiopathic inflammatory myopathy (a muscle inflammation disease) with autoantibodies in the blood. The disease must have come back or not responded after earlier treatments.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Active seropositive autoimmune disease (Sjogren's disease or idiopathic inflammatory myopathy) that has come back or not responded to treatment.
- Earlier treatment
- At least 2 prior or ongoing treatments. People who had a BCMA-targeted therapy before cannot join.
- Biomarker or test result
- Seropositive disease: autoantibodies found in a blood test.
Main reasons for not taking part
- Earlier treatment with a BCMA-targeted therapy
- Serious infection within 3 months of screening
- Major surgery within 3 months of screening or planned during the study
- Pregnant or breastfeeding
- Body weight under 50 kg (110 lb)
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Diagnosis of active seropositive autoimmune disease
- Relapsed/refractory after ≥2 prior/ongoing treatments
- Body weight ≥ 50 kg
- Willing to comply with and study requirements and procedures
Who cannot take part
- Previous treatment with a BCMA-targeted therapy
- Major surgery within 3 months of screening or planned during the study
- Clinically significant infection within 3 months of screening
- Pregnant or breastfeeding
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in New Zealand.
Also in 1 other country, 1 site
- Waikato HospitalHamilton, New ZealandContact: Study SponsorTaking people
About the trial
What the trial wants to find out
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.
The group in the trial
- OM336 Dose EscalationTreatment being tested
Participants will receive OM336 via subcutaneous injection in ascending dose cohorts
Treatment: OM336
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Sjogren's Disease or Idiopathic Inflammatory Myopathy
- Plain-language title
- OM336 for Sjogren's disease or inflammatory muscle diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT07229144, who can take part
- Record updated
- 15 June 2026